Skip to main content

Valganciclovir Dosage

Medically reviewed by Drugs.com. Last updated on Nov 21, 2023.

Applies to the following strengths: 450 mg; 50 mg/mL

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for CMV Retinitis

Induction dose: 900 mg orally twice a day for 21 days
Maintenance dose: 900 mg orally once a day

Comments:


Use: For the treatment of CMV retinitis in patients with AIDS

Usual Adult Dose for CMV Prophylaxis

900 mg orally once a day

Duration of therapy:


Comments:

Use: For the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant recipients at high risk (donor CMV seropositive/recipient CMV seronegative)

Usual Pediatric Dose for CMV Prophylaxis

1 month to 16 years (heart transplant recipients) or 4 months to 16 years (kidney transplant recipients):
The recommended once-daily oral dose is based on BSA and CrCl derived from a modified Schwartz formula, and is calculated using the following equation:

Pediatric dose (mg) = 7 x BSA x CrCl (calculated using a modified Schwartz formula)


Mosteller BSA (m2) = the square root of (height [cm] x weight [kg] divided by 3600)

Schwartz CrCl (mL/min/1.73 m2) = k x height (cm) divided by serum creatinine (mg/dL)

k values:

Maximum dose: 900 mg orally once a day

Older than 16 years: 900 mg orally once a day

Duration of therapy:

Comments:

Uses: For the prevention of CMV disease:

Usual Pediatric Dose for CMV Retinitis

Older than 16 years:
Induction dose: 900 mg orally twice a day for 21 days
Maintenance dose: 900 mg orally once a day

Comments:


Use: For the treatment of CMV retinitis in patients with AIDS

Renal Dose Adjustments

Adults and adolescents older than 16 years:
CrCl 40 to 59 mL/min:


CrCl 25 to 39 mL/min:

CrCl 10 to 24 mL/min:

Pediatrics: Dosing in pediatric patients with renal dysfunction can be done using the recommended equations as CrCl is a component in the calculation.

Comments: Serum creatinine levels or CrCl should be monitored regularly during therapy; dose should be adjusted as appropriate.

Liver Dose Adjustments

Data not available

Comments: Safety and efficacy have not been established in patients with liver dysfunction.

Precautions

US BOXED WARNINGS:


Safety and efficacy have not been established for children (up to 16 years) for prevention of CMV disease in pediatric liver transplant patients, in heart transplant patients younger than 1 month, in kidney transplant patients younger than 4 months, in pediatric AIDS patients with CMV retinitis, or in infants with congenital CMV infection.

Consult WARNINGS section for additional precautions.

Dialysis

Adults and adolescents older than 16 years:
Hemodialysis (CrCl less than 10 mL/min): Not recommended.

Comments: A reduced dose of ganciclovir is recommended; the manufacturer product information for ganciclovir should be consulted.

Other Comments

Administration advice:


Storage requirements:

Reconstitution/preparation techniques:

General:

Monitoring:

Patient advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.